C. Lascoux

发表

Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)

R. Tubiana, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients

E. Vicaut, G. Carcelain, B. Autran, 2006, AIDS.

Pharmacokinetics and Tolerability of Intravenous Trecovirsen (GEM®91), an Antisense Phosphorothioate Oligonucleotide, in HIV‐Positive Subjects

R. Tubiana, C. Katlama, P. Schechter, 1999, Journal of clinical pharmacology.

[From retroperitoneal fibrosis to gastric linitis].

D. Farge, L. Florea, L. Amrouche, 2009, La Revue de medecine interne.

Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy.

S. Chevret, C. Pellet, C. Lebbé, 2001, The Journal of investigative dermatology.

Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.

C. Katlama, C. Rouzioux, F. Raffi, 2015, The Lancet. Infectious diseases.

Short communication: evidence of HIV type 1 complex and second generation recombinant strains among patients infected in 1997-2007 in France: ANRS CO06 PRIMO Cohort.

C. Rouzioux, P. Frange, L. Meyer, 2010, AIDS research and human retroviruses.

False-negative Results of Human Immunodeficiency Virus (HIV) Rapid Testing in HIV Controllers.

É. Oksenhendler, C. Katlama, D. Neau, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Recent developments in the treatment of HIV disease.

D. Séréni, C. Lascoux, Daniel Sereni, 2001, European journal of internal medicine.

Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.

P. Morlat, C. Rouzioux, L. Meyer, 2022, The Journal of antimicrobial chemotherapy.

HIV type 2 demyelinating encephalomyelitis.

A. Moulignier, A. Bourgarit, C. Lascoux, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Treatment with adalimumab for severe immune reconstitution inflammatory syndrome in an HIV-infected patient presenting with cryptococcal meningitis.

A. Alanio, A. Guéguen, A. Zagdanski, 2016, Medecine et maladies infectieuses.

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study

R. Tubiana, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Factors associated with virological response in HIV‐infected patients failing antiretroviral therapy: a prospective cohort study

É. Oksenhendler, S. Chevret, S. Fournier, 2005, HIV Medicine.

Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial.

J. Ragnaud, H. Fleury, B. Hoen, 1999, The Journal of infectious diseases.

First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases.

D. Farge, E. Tuleja, D. Séréni, 2006, AIDS.